Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation in Pediatric Relapsed IBD
NCT02108821Phase 1Completed
- Sponsor
- Children's Mercy Kansas City
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC), sponsored by Children's Mercy Kansas City. Primary endpoint: Number of Occurrences of Adverse Events at 6 months. Started Mar 2014; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02108821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108821.